Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
IPO Year: 1999
Exchange: NYSE
Website: agilent.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2025 | $135.00 → $145.00 | Underweight → Equal Weight | Barclays |
| 8/28/2024 | $157.00 | Overweight | Wells Fargo |
| 7/10/2024 | $135.00 → $150.00 | Neutral → Buy | Citigroup |
| 6/27/2024 | Outperform → Peer Perform | Wolfe Research | |
| 6/3/2024 | $135.00 | Hold | Jefferies |
| 4/5/2024 | $145.00 → $163.00 | Hold → Buy | Stifel |
| 12/13/2023 | $140.00 | Outperform | Wolfe Research |
| 12/12/2023 | $130.00 → $133.00 | Buy → Neutral | BofA Securities |
| 11/17/2023 | $163.00 → $125.00 | Buy → Neutral | UBS |
| 9/28/2023 | $123.00 | Mkt Perform | Bernstein |